



EORTC Trial 55994:
**Randomized phase III study of neoadjuvant
chemotherapy followed by surgery vs.
concomitant radiotherapy and chemotherapy in
FIGO stage Ib2, IIa > 4 cm or IIb cervical cancer.**

EORTC Study Coordinators:

- Dr. G. Kenter
- Dr. F. Landoni
- Dr. S. Greggi
- Dr. A. Colombo

EORTC




Main eligibility criteria:

- Cervical carcinoma of one the following histological types:
 - squamous cell carcinoma
 - adenosquamous cell or adenocarcinoma
- FIGO stage Ib2, IIa > 4 cm or IIb.
- WHO performance status 0-2.
- Age 18-75.
- No prior irradiation or chemotherapy.

EORTC



Treatment Scheme:



EORTC



Stratification factors:

- Institution
- FIGO stage
- Age (18-50; 51-75)
- Histological subtype (adenomatous vs. non-adenomatous component)

EORTC



Trial Endpoints:

Main endpoint:

- Overall survival

Secondary endpoints:

- Progression free survival
- Toxicity
- Quality of life

EORTC



Trial Status:

- Date of activation: 19/03/2002.
- The first patient was randomized on the 23/05/2002.
- 686 patients are required.
- An interim analysis will be performed after the first 100 deaths.

EORTC